AI
Commented by Fabian Lorenz on November 6th, 2025 | 07:00 CET
Does Germany have a drone problem? Hensoldt, TKMS, Helsing, and NEO Battery Materials!
Drone alerts at German and European airports! At the same time, criticism of Germany's defense policy is growing louder. Is the federal government investing too much in tanks and other heavy equipment and too little in drones and counter-drone systems? This opinion is shared not only by the head of Germany's new drone star, Helsing, but also by several other experts. The situation is quite different in the rest of the world, where demand for drones is rising significantly. NEO Battery Materials is also benefiting from this trend. The Company recently secured an existing factory in South Korea for the production of high-performance batteries, and the first million-dollar orders are already in place. And what is TKMS doing? Its share price has slipped in recent days. Could large orders bring new momentum?
Read
Commented by Fabian Lorenz on November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
Read
Commented by Armin Schulz on November 4th, 2025 | 07:05 CET
The three stocks for the AI revolution: How to profit with Alibaba, Aspermont, and Palantir
In an era where autonomous AI agents manage complex processes and data-driven decisions generate over 50% more growth, technological advancement determines market dominance. Even traditional industries such as mining are experiencing a revolution through real-time data. Investing in this future means backing the right pioneers. Three companies, Alibaba, Aspermont, and Palantir, exemplify how these megatrends can be capitalized on.
Read
Commented by Armin Schulz on October 30th, 2025 | 07:25 CET
A new era in medicine is dawning: How Novo Nordisk, NetraMark Holdings, and Bayer are benefiting from AI and personalization
The healthcare industry is on the cusp of a new era, driven by AI-powered personalized therapies that are not only prolonging lives but also reshaping markets worth billions. Those who identify the pioneers of this transformation early on could benefit from extraordinary growth opportunities. Three companies, Novo Nordisk, NetraMark Holdings, and Bayer, are positioning themselves at the heart of this profitable field with groundbreaking technologies and therapies.
Read
Commented by Fabian Lorenz on October 29th, 2025 | 07:25 CET
BIG NEWS at Nordex! OpenAI fuels the AI energy boom! Siemens Energy and dividend stock RE Royalties benefit
Good news for the energy sector. OpenAI is calling on the US government to expand its energy infrastructure. Siemens Energy owes its 1,000% rally to the AI boom. However, analysts are cautioning ahead of the next quarterly results. Another hidden gem in the energy sector is RE Royalties. The Canadian company primarily finances renewable energy projects across North America, combining steady growth with an attractive dividend yield of over 10%. The CEO recently detailed the firm's strategy in an interview. It is not entirely clear where Nordex's sudden growth is coming from. In any case, the stock market is celebrating the forecast upgrade.
Read
Commented by Fabian Lorenz on October 28th, 2025 | 07:15 CET
Better than BioNTech, Evotec & Co.? BioNxt Solutions faces key milestones and is considering an AI takeover – Stock in an upward trend
An exciting alternative to Evotec, BioNTech, and similar companies is BioNxt Solutions. The Canadian-German company's business model is a refreshing departure from traditional biotech companies with their huge research costs. BioNxt reformulates already approved active ingredients. For instance, Ozempic is set to be taken orally instead of by injection in the future. The sublingual cladribine formulation for multiple sclerosis is already well advanced, with its preclinical phase nearing completion. At the same time, CEO Hugh Rogers is considering an acquisition in the field of artificial intelligence to further accelerate development processes. The aforementioned development in the billion-dollar obesity market is also exciting. If a breakthrough succeeds, the Company could soon become a takeover candidate for Big Pharma.
Read
Commented by Fabian Lorenz on October 24th, 2025 | 07:25 CEST
Yesterday +16%! D-Wave explodes again! Siemens Energy and First Hydrogen shares benefit from AI's energy hunger
What a bounce for D-Wave. After a sharp correction yesterday, the quantum stock rose 16%. Is the Trump administration getting involved in quantum companies? That is the rumor making the rounds. Meanwhile, the energy hunger of AI data centers is also keeping the stock market on tenterhooks. One beneficiary from Germany is Siemens Energy. The stock is running like clockwork. Small modular reactors (SMRs) are a huge topic in North America. The Canadian government is providing massive support to industry, which should benefit First Hydrogen. The Company plans to combine its hydrogen expertise with SMR technology. So - buy now?
Read
Commented by Carsten Mainitz on October 23rd, 2025 | 07:25 CEST
AI hidden gem NetraMark Holdings is poised for a price surge, TeamViewer crash, and Novo Nordisk supervisory board resigns! What to do?
Artificial intelligence (AI) is widely regarded as a key technology with enormous potential across all industries. The use of AI opens up new opportunities, particularly in the biotechnology and pharmaceutical industries: from faster identification of potential active ingredients to more precise diagnostics and the automation of complex laboratory processes. Companies that make targeted use of AI gain competitive advantages in a highly competitive environment. Following a broad-based bull market, it is worth exploring promising second-tier players.
Read
Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST
AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk
Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!
Read
Commented by Armin Schulz on October 17th, 2025 | 07:05 CEST
Three stocks, one trend: Jump on the momentum bandwagon with Almonty Industries, AMD, and ASML
The stock market often rewards those who recognize a trend before it becomes mainstream. This is not about short-term speculation, but about identifying companies with strong fundamental tailwinds that can drive prices higher over the long term. This momentum is fueled by structural factors: global technology shifts, geopolitical realignments, and the reorganization of critical supply chains. There is a reason why the saying goes: Go with the flow! Almonty Industries, AMD, and ASML each embody these powerful forces and currently have strong momentum on their side. Let's take a closer look.
Read